Pacific Biosciences of California
PACB
1.63
-0.13
-7.39%
Pacific Biosciences of California
US · PACB
#3373 by market cap
1.63
-0.13
-7.39%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:52
Recent news
-
Rating change
TR | OpenAI - 4o Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5Market Newswire · 2025/8/24
-
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $3Market Newswire · 2026/11/5
-
Rating change
Morgan Stanley Initiates Pacific Biosciences of California(PACB.US) With Hold Rating, Announces Target Price $2Market Newswire · 2025/8/11
-
Rating change
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $2.5Market Newswire · 2026/10/23
-
Rating change
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2Market Newswire · 2026/8/6
-
Rating change
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3Market Newswire · 2026/8/6
-
Rating change
Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)TipRanks · 2026/8/6
-
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Raises Target Price to $2Market Newswire · 2026/11/5
-
Earnings Flash (PACB) Pacific Biosciences of California, Inc. Posts Q3 Adjusted Loss $0.11 per Share, Vs. FactSet Est of $-0.13MT Newswires · 2026/11/5
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX)TipRanks · 2026/5/9
-
Rating change
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3Market Newswire · 2026/8/17
-
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Announces Target Price $3Market Newswire · 2026/11/6
-
Rating change
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy RatingMarket Newswire · 2026/9/11
-
Rating change
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2Market Newswire · 2025/11/10
-
UBS Initiates Pacific Biosciences of California(PACB.US) With Hold Rating, Announces Target Price $2.7Market Newswire · 2026/11/9
-
Rating change
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2Market Newswire · 2025/11/11
-
Rating change
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1Market Newswire · 2026/4/14
-
Rating change
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25Market Newswire · 2026/10/7
-
Rating change
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5Market Newswire · 2025/10/3
-
Rating change
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2Market Newswire · 2026/2/13
-
Rating change
A Quick Look at Today's Ratings for Pacific Biosciences of California(PACB.US), With a Forecast Between $2 to $3Market Newswire · 2025/5/10
-
Rating change
Bernstein Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $1.7Market Newswire · 2025/8/8
-
Rating change
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Cuts Target Price to $1.25Market Newswire · 2025/5/16
-
Rating change
Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2Market Newswire · 2025/5/28
-
Rating change
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $2Market Newswire · 2025/4/11
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:52:58 · For reference only, not investment advice and not tailored to your situation.
Pacific Biosciences of California discussion 0 comments